JNNP: The effect of alemtuzumab on the efficacy and safety outcomes of patients with multiple sclerosis

Although some disease-modified therapies (DMTs) have been approved in the past decade, the treatment of relapsing-remitting multiple sclerosis remains challenging.

Alemtuzumab (ALEM) is an anti-CD52 monoclonal antibody that has been shown to control in untreated patients (CARE-MS I) and patients with poor response to first-line DMT (CARE-MS II) Very effective in disease activity.

Eleven adult patients with active MS who were considered eligible for ALEM treatment according to the latest prescribing standards were included in the prospective planned cohort study (NCT04082260).

Clinical data is also needed to assess the potential impact of DMT sequencing on the immune system to assist the decision-making process in clinical practice.

170 patients who did not respond to NTZ, FTY, IFN or DMF at the beginning of treatment or before were identified and received at least two courses of ALEM treatment.

Regression analysis showed that among all the previously used DMT, the Fingemod pretreatment group (first relapse time n=33 hours (HR 5.

In a medical setting, this article proves that patients who have previously received Fengliemod have poor disease control after alemtuzumab treatment, and the risk of secondary autoimmunity is increased.